A dual antagonist of TP1 and EP4 receptors that inhibit TXA2-induced platelet aggregation with IC50 of 0.26 uM.

A dual action as an alkylating agent and topoisomerase inhibitor with potent activity against anthracycline- and cisplatin-resistant tumor cancer.

A drug-like small molecule that prevents aminoglycoside-induced hair cell death in zebrafish and in mammals..

A doxorubicin analog that demonstrates anti-cancer activity without cardiotoxicity, does not inhibit topoisomerase IIβ activity at 100 uM.

A donepezil analog that can moderately inhibit acetylcholinesterase and metal-induced Aβ aggregation in vitro and shows disassembly of Aβ aggregates.

A donepezil analog that can moderately inhibit acetylcholinesterase and metal-induced Aβ aggregation in vitro and shows disassembly of Aβ aggregates.

A donepezil analog that can moderately inhibit acetylcholinesterase and metal-induced Aβ aggregation in vitro and shows disassembly of Aβ aggregates.

A direct soluble guanylate cyclase (sGC) stimulator that acts independently of nitric oxide (NO).

A dipeptide antibiotic that inhibits the initiation of protein synthesis.

A derivative of 8-hydroxyquinoline that has selectivity for rescuing the distinct toxicities caused by the expression of TDP-43, α-synuclein or polyglutamine proteins.

A cytokinin analog that displays potent antiproliferative activity against various human cancer cell lines.

A cyclooxygenase inhibitor. Structurally similar to Tenoxicam. An anti-inflammatory and an analgesic.

A counterstain for background autofluorescence in fluorescence and immunofluorescence histochemistry, also is the first small molecule prion protein (PrP) ligand capable of inhibiting Aβ binding.

A coumarin-based HIV-1 viral protein R (Vpr) inhibitor, inhibits Vpr-dependent viral infection of human macrophages.

A conjugate of glucose and active alkylating moiety of ifosfamide with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters.

A combined adenosine receptor antagonist, p38 MAPK and PDE4 inhibitor, inhibits A1, A2b and A3 receptor (IC50=19, 21 and 80 nM), p38α, p38β and PDE4D (IC50=87, 400 and 22 nM).

A clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux.

A clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux.

A class Ic antiarrhythmic agent used to prevent and treat tachyarrhythmias, works by blocking the Nav1.5 sodium channel in the heart, slowing the upstroke of the cardiac action potential.

A chemical probe that consists of Ibrutinib linked to biotin via a long chain linker, has IC50 of 0.755-1.02 nM for Btk kinase.

A cerebral vasodilator that acts as a calcium blocker.

A ceramide analog that inhibits glucosylceramide synthase (GCS), reduces the synthesis of sphingosine and its derivatives, increases cellular ceramide, and induces cell cycle arrest. .

A cellular cholesterol modifier that can form soluble inclusion complex with cholesterol.

A cell-permeable, small molecule inhibitor of the transcription factor STAT5 that exhibits anticancer activity and inhibits the growth of A549, HL-60 and K562 cells with IC50 of 8, 5 and 8 uM, respectively..

A cell-permeable small molecule inhibitor of Fumarase (fumarate hydratase), an enzyme of the tricarboxylic acid cycle (TCA cycle).

A cell-permeable mitochondrial calcium uptake inhibitor that binds to mitochondria with high affinity (Kd=340 pM) and blocks Ca2+ uptake into mitochondria in vitro with IC50 of 184 pM.

A cell-permeable inhibitor of the KIX-KID interaction and CREB-mediated gene transcription (IC50=2.26 uM).

A cell permeable, mechanistically unique inhibitor of protein sumoylation.

A cell permeable CBP bromodomain inhibitor with Kd of 19 uM.

A cell permeable CBP bromodomain inhibitor with Kd of 19 uM.